CVRx, Inc. (CVRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1266381052
CVRx, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 56.65 m USD |
| Gross profit | 48.34 m USD |
| Operating income | -51.27 m USD |
| EBIT | -47.50 m USD |
| Net income | -53.31 m USD |
| Diluted EPS – continuing operations | -2.04 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CVRx, Inc.
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
More stocks
- Coronado Global Resources Inc. (CODQL)
- HWH International Inc. (HWH)
- SELECTIS HEALTH, INC. (GBCS)
- CareView Communications Inc (CRVW)
- BOXABL Inc. (BXBL)
- DSwiss Inc (DQWS)
- Starco Brands, Inc. (STCB)
- HG Holdings, Inc. (STLY)
- MDWerks, Inc. (MDWK)
- SemiLEDs Corp (LEDS)
- Pineapple Financial Inc. (PAPL)
- Track Group, Inc. (TRCK)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.